Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Medicament combination preparation for treating bacterial infection

A bacterial and drug technology, applied in the field of drugs for the treatment of bacterial infections, can solve the general trend of society that is not conducive to reducing medical costs, reduce the dosage of antibiotics, and increase the cost of treatment, and achieve beneficial bacterial infections, maintain curative effects, and significantly improve society. Benefit and economic effect

Active Publication Date: 2008-08-20
CHENGDU DIAO JIUHONG PHARMA FACTORY
View PDF1 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Moreover, the disclosed ratio of thymosin to cefazolin sodium is 1:5 to 1:3333, the range is very wide, and it is difficult for ordinary technical personnel to choose the dosage and operation. In addition, it does not necessarily significantly reduce the amount of antibiotics, from alleviating bacterial resistance. On the other hand, there are many varieties and large quantities of the compound preparations, which will inevitably increase the cost of treatment, which is not conducive to the social trend of reducing medical costs.
At present, there is no report on the combination of thymosin α1 and antibiotics

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicament combination preparation for treating bacterial infection
  • Medicament combination preparation for treating bacterial infection
  • Medicament combination preparation for treating bacterial infection

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Embodiment 1 Thymosin α1 and ceftriaxone sodium medicine combined preparation

[0034] Each vial contains 1 mg of thymosin α1 sterile freeze-dried powder, 7 in total; each vial contains 30 mg of sterile ceftriaxone sodium dry powder, 2 in total, put them in the same package, and use them together according to the instructions. The thymosin α1 and ceftriaxone sodium both meet the requirements of the 2005 edition of the Chinese Pharmacopoeia.

Embodiment 2

[0035] The drug combination preparation of embodiment 2 thymosin alpha 1 and ceftriaxone sodium

[0036] Each vial contains 3 mg of thymosin α1 sterile freeze-dried powder, a total of 7; each vial contains 47.5 mg of sterile ceftriaxone sodium dry powder, a total of two, put in the same package, and use them together according to the instructions. The thymosin α1 and ceftriaxone sodium both meet the requirements of the 2005 edition of the Chinese Pharmacopoeia.

Embodiment 3

[0037] The drug combination preparation of embodiment 3 thymosin alpha 1 and ceftriaxone sodium

[0038] The independently packaged preparation contains 10 vials, and each bottle contains 3 mg of thymosin α1 sterile freeze-dried powder. The built-in instructions and the label on the bottle indicate that the preparation is used in combination with 60 mg of ceftriaxone sodium. The independently packaged preparation has a built-in vial containing 60 mg of dry powder of sterile ceftriaxone sodium, and the built-in instructions and the label on the bottle indicate that the preparation is used in combination with 3 mg of thymosin α1. The thymosin α1 and ceftriaxone sodium both meet the requirements of the 2005 edition of the Chinese Pharmacopoeia.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a drug combination package, comprising thymosin Alpha 1 and antibiotic with a certain ratio; the drug combination package has the advantages that the optimal combination between drugs is realized within the range of the ratio; the using dosage of the antibiotic and the thymosin Alpha 1 can be greatly reduced as well as ensuring the therapeutic effect, thus being propitious to control the generation of the drug resistance for bacteria, which has very important significance for alleviating increasingly serious drug resistance; on the other hand, due to the reduced using dosage, the treatment cost for the sufferer is lowered, which is propitious to resolve the ever increasing social medical burden problem.

Description

technical field [0001] The invention relates to the field of drugs for treating bacterial infection, in particular to the combined drug of thymosin α1 and antibiotics. Background technique [0002] With the extensive use of antibiotics in clinical practice, bacterial drug resistance has gradually emerged and has become a prominent problem in clinical practice. The development of new, more potent antibiotics could go some way towards addressing the growing problem of drug resistance. However, the use of antibiotics is bound to be accompanied by the emergence of drug resistance, which is a never-ending process. [0003] Establish reasonable and effective antibiotic use methods and principles to reduce the frequency and dosage of antibiotics; especially through optimized drug combination and synergistic effects, minimize the amount of antibiotics, and achieve the same or better than before reduction Treatment effect is the common expectation of patients and medical staff. A ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/19A61K45/06A61P31/04
Inventor 黄沛何民刘忠荣王若竹
Owner CHENGDU DIAO JIUHONG PHARMA FACTORY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com